TH-PVP is a cathinone derivative marketed and sold as a designer drug. Its initial discovery took place in a forensic laboratory in Hungary in 2015. Since then, it has been detected in various countries worldwide, including Spain, Belgium, Poland, Turkey, and Brazil. In vitro, pharmacological studies have revealed that TH-PVP can inhibit monoamine neurotransmitters’ reuptake while facilitating their release. Notably, it displays a certain level of selectivity for serotonin. However, it is essential to note that TH-PVP failed to induce stimulant effects in animal studies, and its pharmacological profile aligns more closely with that of sedative empathogens, such as MDAI and 5-Methyl-MDA.
TH-PVP is a synthetic cathinone derivative sold as a designer drug.
2. When was TH-PVP first identified?
TH-PVP was first identified by a forensic laboratory in Hungary in 2015.
3. Where has TH-PVP been found?
TH-PVP has been detected in various countries worldwide, including Spain, Belgium, Poland, Turkey, and Brazil.
4. What are the pharmacological properties of TH-PVP?
In vitro pharmacological studies have shown that TH-PVP inhibits the reuptake of monoamine neurotransmitters and promotes their release. It exhibits some selectivity for serotonin.
5. Does TH-PVP produce stimulant effects in animals?
No, TH-PVP failed to produce stimulant effects in animal studies.
6. How does the pharmacological profile of TH-PVP compare to other substances?
The pharmacological profile of TH-PVP is comparable to that of sedating empathogens like MDAI and 5-Methyl-MDA.
7. Is TH-PVP legal and regulated?
The legal status of TH-PVP can vary by country and region. It is essential to check local laws and regulations regarding its possession, sale, or use, as it may be subject to legal restrictions in different jurisdictions.
8. What are the potential risks and side effects associated with TH-PVP use?
Information about the effects and risks of TH-PVP may be limited. Like any designer drug, it may have potential health risks and side effects. Caution and responsible use are advised.
“RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” is a regulatory document in Brazilian Portuguese issued by Anvisa that lists controlled substances. It was last published on July 24, 2023, in the Diário Oficial da União.
The “EMCDDA–Europol 2015 Annual Report” provides information on the implementation of Council Decision 2005/387/JHA. This report sheds light on drug-related issues and was archived as a PDF.
Researchers conducted spectroscopic studies to identify and derivatize selected cathinones. The findings were published in “Forensic Science International” in September 2016.
Ion mobility spectrometry and high-resolution mass spectrometry were used as methodologies to rapidly identify new psychoactive substances. This research was detailed in a November 2018 article published in the “Journal of Chromatography A.”
A study published in “Drug Testing and Analysis” in March 2018 examined the prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population.
Researchers identified and structurally characterized synthetic cathinones, including various derivatives. This work was published in “Forensic Toxicology” in July 2019.
“New psychoactive substances in Turkey” is a study that assessed narcotics cases between 2016 and 2017 in Ankara, Turkey. The findings were published in “Forensic Science International” in January 2019.
A six-year retrospective study conducted in the state of Santa Catarina, Brazil, compared the prevalence of new psychoactive substances (NPS) to LSD in seized blotter papers. The results were published in “Forensic Science International” in October 2019.
Researchers investigated the structure-activity relationships of bath salt components, including substituted cathinones and benzofurans, at biogenic amine transporters. Their findings were published in “Psychopharmacology” in March 2019.
A study assessed the locomotor activity and discriminative stimulus effects of five novel synthetic cathinone analogs in mice and rats. The research was published in “Drug and Alcohol Dependence” in June 2019.